Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, Eliza A. Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John A. Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David Linch

    Research output: Contribution to journalArticlepeer-review

    Fingerprint

    Dive into the research topics of 'Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles'. Together they form a unique fingerprint.

    Medicine and Dentistry

    Immunology and Microbiology

    Pharmacology, Toxicology and Pharmaceutical Science